Diagnostic Potential of miR‑451a in Myelodysplastic Syndromes
DOI:
https://doi.org/10.14748/775sfj75Keywords:
Myelodysplastic syndromes, plasma microRNAs, microRNA-451a, Diagnostic biomarkersAbstract
Introduction:
Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by ineffective hematopoiesis and a risk of progression to acute myeloid leukemia. Diagnosis often requires integrating clinical, morphological, and genetic data, but distinguishing MDS from overlapping conditions remains challenging. MiR-451a plays a crucial role in erythropoiesis and has shown potential as a diagnostic biomarker, though existing data on its expression in MDS are conflicting.
Aim:
The aim of the study is to evaluate miR-451a expression levels in MDS patients and healthy controls and to assess variations in expression among different MDS subgroups.
Materials and Methods:
Plasma samples from 40 MDS patients and 10 healthy controls were analyzed for the expression levels of miR-451a using quantitative real-time PCR (qPCR). Statistical analysis was performed to compare expression levels between the groups.
Results:
MiR-451a levels were significantly lower in MDS patients compared to healthy controls (median 0.8215 vs. 2.132; p < 0.0001). ROC analysis revealed high diagnostic accuracy (AUC = 0.9175), with a threshold of 1.161 providing 70.0% sensitivity and 100.0% specificity. Additionally, miR-451a levels were significantly lower in low-risk MDS patients compared to high-risk patients (p = 0.0449). A moderate positive correlation was observed between miR-451a and ferritin (p < 0.05), suggesting a link with iron metabolism.
Conclusion:
Our findings demonstrate that miR-451a is significantly downregulated in MDS patients, highlighting its potential as a diagnostic biomarker. While its prognostic utility remains uncertain, miR-451a shows promise for non-invasive diagnosis.
References
[1] Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26): 2488-2498., 2014. URL https://pubmed.ncbi.nlm.nih.gov/25426837/.
[2]Hebeda KM, Tzankov A, Boudova L, et al Challenges in diagnosing myelodysplastic syndromes in the era of genetic testing: Proceedings of the 13th workshop of the european bone marrow working group. Pathobiology : journal of immunopathology, molecular and cellular biology,, 86(1): 62–75, 2019. doi: https://doi.org/10.1159/000489678. URL https://pubmed.ncbi.nlm.nih.gov/29982244/.
[3] Malcovati L, Gallì A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017; 129(25): 3371-3378, 2017. URL https://pubmed.ncbi.nlm.nih.gov/28424163/.
[4] Hansen JW, Westman MK, Sjö LD, et al. Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes. Am J Hematol. 2016; 91(12): 1234-1238, 2016. URL https://pubmed.ncbi.nlm.nih.gov/27717004/.
[5] Milunović V, Mandac Rogulj I, Planinc-Peraica A, et al. The role of microRNA in myelodysplastic syndromes: beyond DNA methylation and histone modification. Eur J Haematol, 2016. URL https://doi.org/10.1111/ejh.12735.
[6] Hong Wang, Tong-Tong Zhang, Song Jin, et al. Pyrosequencing quantified methylation level of mir-124 predicts shorter survival for patients with myelodysplastic syndrome. Clin Epigenetics, 9(91), 2017. doi: doi.org/10.1186/s13148-017-0388-5. URL https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-017-0388-5#citeas.
[7] Zuo Z, Calin GA, de Paula HM, et al. Circulating micrornas let-7a and mir-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood, 118(2):413–415, 2011. doi: doi.org/10.1182/blood-2011-01-330704. URL https://ashpublications.org/blood/article/118/2/413/28485/Circulating-microRNAs-let-7a-and-miR-16-predi
[8] Kouhkan F, Hafizi M, Mobarra N, et al. miRNAs: a new method for erythroid differentiation of hematopoietic stem cells without the presence of growth factors. Appl Biochem Biotechnol. 2014;172: 2055–2069, 2014. URL doi:10.1007/s12010-013-0633-0.
[9] Tsuchiya S, Oku M, Imanaka Y, et al. MicroRNA-338-3p and microRNA-451 contribute to the formation of basolateral polarity in epithelial cells. Nucleic Acids Res. 2009;37:3821–3827., 2009. URL doi:10.1093/nar/gkp255.
[10] Dore LC, Amigo JD, Dos Santos CO, et al. A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci U S A. 2008;105:3333–8., 2008. URL https://doi.org/10.1073/pnas.0712312105.
[11] Pase L, Layton JE, Kloosterman WP, et al. miR-451 regulates zebrafish erythroid maturation in vivo via its target gata2. Blood 2009;113:1794–804., 2009. URL DOI: 10.1182/blood-2008-05-155812.
[12] Bandres E, Bitarte N, Arias F et al. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res 2009;15:2281–90., 2009. URL DOI: 10.1158/1078-0432.CCR-08-1818.
[13] Wang R, Wang ZX, Yang JS, et al. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 2011;30:2644–58, 2011. URL https://doi.org/10.1038/onc.2010.642.
[14] Bergamaschi A, Katzenellenbogen BS. Tamoxifen downregulation of miR-451 increases 14-3-3zeta and promotes breast cancer cell survival and endocrine resistance. Oncogene 2012;31:39–47., 2012. URL DOI: 10.1038/onc.2011.223.
[15] Dostalova Merkerova M, Hrustincova A, Krejcik Z, et al. Microarray profiling defines circulating micrornas associated with myelodysplastic syndromes. Neoplasma, 64(4):571–578, 2017. doi: doi.org/10.4149/neo_2017_411. URL https://doi.org/10.4149/neo_2017_411.
[16] Zuo Z, Maiti S, Hu S, et al. Plasma circulating-microrna profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 28(3):373–382, 2015. doi: doi.org/10.1038/modpathol.2014.108. URL https://www.modernpathology.org/article/S0893-3952(22)01907-X/fulltext.
[17] Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood vol. 120,12 (2012): 2454-65, 2012. URL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425443/.
[18] Arber DA, Orazi A, Hasserjian R, et al. Тhe 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20): 2391–2405, 2016. URL https://doi.org/10.1182/blood-2016-03-643544.
[19] T D Schmittgen, K J Livak. Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method. Methods, 25(4):402–8, 2001. doi: doi: 10.1006/meth.2001.1262. URL https://pubmed.ncbi.nlm.nih.gov/11846609/.
[20] Rasmussen KD, Simmini S, Abreu-Goodger C, et al. The mir-144/451 locus is required for erythroid homeostasis. The Journal of experimental medicine, 207(7):1351–1358, 2010. doi: doi:10.1084/jem.20100458. URL https://pubmed.ncbi.nlm.nih.gov/20513743/.
[21] Pileggi C, Di Sanzo M, Mascaro V, et al. Role of serum ferritin level on overall survival in patients with myelodysplastic syndromes: Results of a meta-analysis of observational studies. PloS one, 12(6):e0179016, 2017. doi: doi:10.1371/journal.pone.0179016. URL https://pubmed.ncbi.nlm.nih.gov/28622367/.
